培美曲塞联合草酸铂治疗晚期转移性非小细胞肺癌  

Pemetrexed plus oxaliplatin as salvage therapy for advanced or metastatic NSCLC

作　　者：张明[1] 陆烨[1] 王彬[1] 

机构地区：[1]苏州市立医院东区肿瘤内科,215001

出　　处：《中国现代药物应用》2008年第17期24-25,共2页Chinese Journal of Modern Drug Application

摘　　要：目的本研究探讨培美曲塞联合草酸铂挽救治疗晚期转移性非小细胞肺癌(NSCLC)的疗效和不良反应。方法经病理学或细胞学确诊的晚期转移性肺癌8例,一线治疗失败后,PS评分0～1分,采用培美曲塞联合草酸铂方案,即第1天培美曲塞500mg/m2静脉注射;第2天草酸铂120mg/m2,每3周为1个周期重复,每2个周期评估疗效及不良反应。结果8例可评价疗效者无CR病例,PR2例,SD3例,PD3例,中位TTP4.1月,中位生存时间10.1月,1年生存率62.5%(5/8)。主要不良反应为中性粒细胞减少、胃肠道反应和末梢神经感觉障碍。结论培美曲塞联合草酸铂二线挽救治疗晚期转移性非小细胞肺癌疗效良好,不良反应轻微。Objective To evaluate the efficacy and toxicity of Pemetrexed combined with oxaliplatin （OXA） as Salvage Therapy for advanced or metastatic non-small cell lung cancer. Methods Eight patients with advanced or metastatic NSCLC who had failed to previous chemotherapy had been confirmed with pathology or cytology and PS scale was 0 ~ 1. Patients received pemetrexed 500 mg/m2 on day 1 and oxaliplatin 120 mg/ m2 on day 2 by intravenous infusion, with three weeks as one cycle. All patients who received two or more cycles could be evaluated. Results There was no case with complete response, 2 cases got partial response. 3 cases got stable disease and the rest got progression disease. The median TIP was 4.1 months and median survival time was 10. 1 months and 1 year-survival rate was 62. 5% （5/8）. The common adverse effects were leucopenia, gastrointestinal response. And sensory disability of peripheral nerve. Conclusions Salvage chemotherapy with pemetrexed plus oxaliplafin is effective and feasible for advanced or metastatic NSCLC.

关 键 词：培美曲塞 草酸铂 晚期非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]